NMRA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ('MDD') to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.
THE LEAD PLAINTIFF PROCESS:
Neumora investors may, no later than April 7, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Cloud Headwinds Test Confluent's Recovery Case
Confluent (NASDAQ:CFLT) got whacked, dropping over 30% after its Q2 results, and the headlines were led by Stifel pulling the rating to Hold from Buy and trimming its target to $21 from $30. The note called out slowing net new workload activity, weak new customer adds, continued cloud usage optimization, and a big AI-native customer shifting off Confluent Cloud to a self-managed setup as the main reasons the growth story is hitting a rough patch. Warning! GuruFocus has detected 4 Warning Signs with CFLT. That sharp move sparked pushback. Guggenheim said the sell-off was too extreme, acknowledging churn and a dip in net revenue retention to 114% and an implied cloud exit rate of 18%, but still thinking a 4Q exit rate of 21% and subscription exit rate of 19% are doable, implying roughly 21% full-year subscription growth. Needham kept its Buy call (target now $24 from $26), warning the same large AI customer is creating a low-single-digit cloud headwind in late 2025 even as stronger Confluent Platform expectations help offset it and shift cloud mix to 55% of subscription revenue exiting the year. RBC also pushed back, holding Outperform with a $25 target (down from $28), saying the price drop was overdone even though optimizations will temper 2H consumption and point to a roughly 17.5% cloud exit growth rate in Q4. The story is now a tug-of-war between near-term risk and underlying optionality. The market is pricing the pain, but if the AI customer's cadence normalizes and exit rates stabilize, the pullback could look like a setup. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Morgan Stanley Reaffirms NVIDIA as Top Pick Amid Soaring Chip Demand
NVIDIA Corporation (NASDAQ:NVDA) is one of the . On July 30, Morgan Stanley reiterated the stock as 'Overweight' and raised its price to $200 per share from $170. The analyst noted robust demand for Blackwell chips, which is outpacing supply. Even though supply constraints still persist, the bottleneck will likely ease in the second half of the year. This will, in turn, likely boost earnings. NVIDIA remains Morgan Stanley's top semiconductor pick. 'We think that the increase in enthusiasm for AI semis is justified by long term strength in the business, and raise targets across the board — though some near term constraints remain. PTs higher across the board, stay OW NVDA AVGO ALAB.' NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, providing high-performance GPUs and platforms that power data centers, autonomous vehicles, robotics, and cloud services. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Why Regeneron (REGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key treatments, including its eye care therapy Eylea HD, cancer drug Libtayo, and immunology medicine Dupixent, which all recorded substantial sales increases. After the initial pop the shares cooled down to $546.32, up 0.2% from previous close. Is now the time to buy Regeneron? Access our full analysis report here, it's free. What Is The Market Telling Us Regeneron's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock dropped 19% on the news that the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD). While one trial met its primary endpoint, the other missed, raising concerns about the drug's future and delaying its potential market entry. This setback, likely spooked investors and contributed to the significant decline. Regeneron is down 23.6% since the beginning of the year, and at $546.32 per share, it is trading 54.5% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of Regeneron's shares 5 years ago would now be looking at an investment worth $846.77. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.